Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Invested Capital (2022 - 2025)

BioXcel Therapeutics has reported Invested Capital over the past 4 years, most recently at -$70.5 million for Q4 2025.

  • Quarterly results put Invested Capital at -$70.5 million for Q4 2025, down 617.82% from a year ago — trailing twelve months through Dec 2025 was -$70.5 million (down 617.82% YoY), and the annual figure for FY2025 was -$70.5 million, down 617.82%.
  • Invested Capital for Q4 2025 was -$70.5 million at BioXcel Therapeutics, up from -$72.1 million in the prior quarter.
  • Over the last five years, Invested Capital for BTAI hit a ceiling of $234.3 million in Q2 2022 and a floor of -$96.5 million in Q2 2025.
  • Median Invested Capital over the past 4 years was $38.9 million (2023), compared with a mean of $61.6 million.
  • Biggest five-year swings in Invested Capital: decreased 19.56% in 2023 and later plummeted 617.82% in 2025.
  • BioXcel Therapeutics' Invested Capital stood at $178.2 million in 2022, then plummeted by 74.09% to $46.2 million in 2023, then crashed by 70.5% to $13.6 million in 2024, then plummeted by 617.82% to -$70.5 million in 2025.
  • The last three reported values for Invested Capital were -$70.5 million (Q4 2025), -$72.1 million (Q3 2025), and -$96.5 million (Q2 2025) per Business Quant data.